Publicaciones en las que colabora con Jesús Miguel García-Foncillas López (6)

2011

  1. Association of RRM1 -37A>C polymorphism with clinical outcome in colorectal cancer patients treated with gemcitabine-based chemotherapy

    European Journal of Cancer, Vol. 47, Núm. 6, pp. 839-847

  2. Inhibitor of differentiation-1 as a novel prognostic factor in NSCLC patients with adenocarcinoma histology and its potential contribution to therapy resistance

    Clinical Cancer Research, Vol. 17, Núm. 12, pp. 4155-4166

2010

  1. Dose-finding study and pharmacogenomic analysis of fixed-rate infusion of gemcitabine, irinotecan and bevacizumab in pretreated metastatic colorectal cancer patients

    British Journal of Cancer, Vol. 103, Núm. 10, pp. 1529-1535

  2. Improving disease control in advanced colorectal cancer: Panitumumab and cetuximab

    Critical Reviews in Oncology/Hematology, Vol. 74, Núm. 3, pp. 193-202

2009

  1. Pharmacogenomic analysis of the triplet combination of gemcitabine, oxaliplatin and cetuximab as salvage therapy for metastatic colorectal cancer (mCRC) patients

    EJC SUPPLEMENTS

2007

  1. Epidermal growth factor receptor inhibitors in colorectal cancer treatment: What's new?

    World Journal of Gastroenterology, Vol. 13, Núm. 44, pp. 5877-5887